Phosphagen. Share Discussion Threads

[spaceparallax] 18/3/2008 10:36

Great news. Let's hope that take-up is substantial and can yield a long and strong income stream.

One down, roll-on the next.

[donaferentes] 27/2/2008 10:40

As ever Australian accounts are designed to send yp to sleep before youu find out any material information.

Another year of solid, if stately, progress. My guess is there will be another fund raising (which I assume will not be open to mere AIM shareholders, but restricted to the Australian master-race of investors). They have A$10m cash and a cash burn rate of about the same last year which may increase as they get nearer final trials and eventual release to the market of their excellent products.

One to tuck away and forget for a couple more years when the rewards could be stupendous.

[spaceparallax] 27/2/2008 10:35

Looking good - still investing hard, but the income tide is clearly turning, with tremendous potential for near future add-ons.

[spaceparallax] 19/2/2008 10:21

More good news and the chart's in danger of developing an upward trend.

[spaceparallax] 11/2/2008 10:07

Looking good - should provide a nice income stream later this year.

[hopeless698] 11/2/2008 07:13

Phospha E Trial-Update




RNS Number:6873N
Phosphagenics Limited
11 February 2008

11 February 2008

Company Announcement


Progression of Phosphagenics and

Nestle Nutrition's Phospha E(R) trial


Phosphagenics Limited ("Phosphagenics") (ASX: POH; AIM: PSG; OTCQX: PPGNY) and
Nestle Nutrition (Nestle) today announced that their joint phase 2 human
clinical trial to establish the efficacy of Phosphagenics' Phospha E(R) in the
management of metabolic syndrome is advancing at three sites in Adelaide,
Australia.



Based on current recruitment rates of study participants, the double-blind phase
2 trial, which is fully funded by Nestle, is expected to be completed in
mid-2008.



This phase 2 clinical trial follows two pre-clinical dose response trials
completed by Nestle and Phosphagenics in 2006. The results of those studies
confirmed that, when given orally, Phospha E(R) significantly reduces many of
the key biomarkers associated with metabolic syndrome.



Metabolic syndrome is characterised by a group of risk factors that increase the
risk of diabetes, coronary heart disease and other diseases associated with
plaque build up in artery walls.



The companies have agreed the principal terms of a commercialisation agreement,
which will grant a worldwide exclusive license to Nestle for the use of Phospha
E(R) in medical foods and for Phosphagenics to be the exclusive manufacturer and
supplier of Phospha E(R) to Nestle. The final commercial agreement is due to be
signed on completion of the phase 2 trial.



Harry Rosen, President & CEO at Phosphagenics said: "We believe the agreed terms
will deliver value to all parties and we look forward to building on the already
strong relationship we have with Nestle, the world's largest food company."

[spaceparallax] 31/1/2008 12:43

Looking up today - word must be spreading.

[lgw] 30/1/2008 10:44

From todays news
"However, Phosphagenics said the insulin, oxycodone and Phospha E clinical
programmes will remain its priority for this year."

So we can quietly look forward to the other (potentially company making) three trial results this year.

[theo13] 30/1/2008 10:39

hi rambutan2 - greetings from your SLV Sylvania thread, any chance of putting the ASX:SLV chart in the header?
Many thanks if you can
Theo
PS apologies to all for O/T

[spaceparallax] 30/1/2008 10:30

Further promise.

[waldron] 30/1/2008 08:28

Phosphagenics' combination treatment cut blood cholesterol levels significantly




LONDON (Thomson Financial) - Phosphagenics Ltd said a pre-clinical study of
a combination of its APA-01 product candidate and the atorvastatin drug
significantly reduced blood cholesterol levels and inflammatory proteins
involved in the development of atherosclerosis.
The company said the study results indicated that the combination reduced
total cholesterol levels by up to an additional 12 pct as opposed to
atorvastatin alone.
Phosphagenics also said APA-01, combined with atorvastatin, enhanced the
statin's effects on lowering inflammation that contributes to the development of
atherosclerotic plaques.
The company said it expects APA-01's apparent enhancement of a statin's
anti-inflammatory functions could potentially provide a novel therapeutic
approach to treating atherosclerosis.
However, Phosphagenics said the insulin, oxycodone and Phospha E clinical
programmes will remain its priority for this year.
[e-mail]
rda/slm

[ladybird1] 24/1/2008 16:46

No. Just a bit of a correction after the steady downwards drift. See ASX website for prices & turnover.

[lgw] 24/1/2008 16:05

Did we get an announcement in aussie?.
PSG normally email me any news but nothing in mmailbox.
17% rise there.

[ladybird1] 21/1/2008 17:59

Reflecting, I suppose, the steady falls in the price on ASX and sells/no buys in the UK. Little volume in Aus. trades & the Aus. market taking a right pasting generally, so presumably no sinister underlying reason for the fall.

[spaceparallax] 21/1/2008 13:20

I'm surprised at the slippage, given the upcoming news stream.

[lgw] 17/12/2007 13:16

yes still holding all my psg and put in an order a few mins ago for another £5k.
PSG are still well out of the radar. Good chance for the extremely patient imo.

[spaceparallax] 17/12/2007 09:58

Another step towards the pot of gold.

[ladybird1] 17/12/2007 00:45

You have to laugh, really. Just looked at the ASX & the stock's down 2% on 123k traded, quite reasonable volume for this stock by this time of day. It is, of course, only early days for the application, but even so.

[rambutan2] 16/12/2007 23:28

17/12/07: Phosphagenics Limited ("Phosphagenics") (ASX: POH, AIM: PSG, OTCQX: PPGNY) today announced positive results of its Phase 1 clinical trial that showed its delivery technology, TPM, delivered leading pain-relief drug oxycodone through the skin without causing any disruption or irritation...

A collaborative program is now under way with a world leading patch development company to incorporate the current formulation into a patch system. Plans are also underway to undertake a pivotal clinical study in the first half of 2008....

[ladybird1] 13/12/2007 12:16

I trust Mr.Rosen's retirement will in the end be well funded!

[rambutan2] 12/12/2007 23:59

for the record...

On Friday 7 December 2007 Paroha Nominees Pty Ltd in its capacity as trustee for the Paroha Nominees Pty Ltd < Superannuation Fund A/C > being a fund in which Mr Rosen may have an entitlement as a beneficiary acquired, through an on-market transaction in the ordinary course of trading of the Australian Stock Exchange, 96,293 ordinary fully paid Phosphagenics Limited shares at A$0.225 a share. Mr Rosen is also a director of the trustee company.

He now holds 10.63% of shares.

[spaceparallax] 12/12/2007 09:02

Merely a premature feed - our day will come.

[jaydeee] 11/12/2007 23:23

though we had a nice surprise today - yahoo were quoting the stock at 68p up 600% on the day. Shame it turns out to be bad "feed". One day....hopefully.....